Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell
MT Newswires Live
Yesterday
Scholar Rock (SRRK) has received US Food and Drug Administration approval for Isembyld to treat spinal muscular atrophy in certain patients aged two years and above, the company said Friday.
Isembyld is expected to ship in the coming days, Scholar Rock said, adding that the company has received a rare pediatric disease priority review voucher that may be used to obtain priority review for a future marketing application.
Spinal muscular atrophy is a severe neuromuscular disease that leads to an irreversible loss of motor neurons and progressive muscle wasting.
Scholar Rock shares were up 8.6% in premarket activity Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.